D
Burning Rock Biotech Limited
BNR
$5.76
$0.264.73%
D
Sell
3/14/2025Upgraded
Burning Rock Biotech Limited (BNR) was upgraded to D- from E+ on 3/14/2025 due to an increase in the volatility index and total return index.
Burning Rock Biotech Limited (BNR) was upgraded to D- from E+ on 3/14/2025 due to an increase in the volatility index and total return index.
E
Sell
2/21/2025Downgrade
Burning Rock Biotech Limited (BNR) was downgraded to E+ from D- on 2/21/2025 due to a decline in the volatility index.
Burning Rock Biotech Limited (BNR) was downgraded to E+ from D- on 2/21/2025 due to a decline in the volatility index.
D
Sell
2/5/2025Upgraded
Burning Rock Biotech Limited (BNR) was upgraded to D- from E+ on 2/5/2025 due to a noticeable increase in the volatility index, growth index and total return index. Earnings per share increased from -$16.51 to -$4.837, EBIT increased 69.24% from -$17.53M to -$5.39M, and operating cash flow increased 24.48% from -$5.6M to -$4.23M.
Burning Rock Biotech Limited (BNR) was upgraded to D- from E+ on 2/5/2025 due to a noticeable increase in the volatility index, growth index and total return index. Earnings per share increased from -$16.51 to -$4.837, EBIT increased 69.24% from -$17.53M to -$5.39M, and operating cash flow increased 24.48% from -$5.6M to -$4.23M.
E
Sell
10/18/2024Upgraded
Burning Rock Biotech Limited (BNR) was upgraded to E+ from E on 10/18/2024 due to an increase in the volatility index.
Burning Rock Biotech Limited (BNR) was upgraded to E+ from E on 10/18/2024 due to an increase in the volatility index.
E
Sell
10/3/2024Downgrade
Burning Rock Biotech Limited (BNR) was downgraded to E from E+ on 10/3/2024 due to a noticeable decline in the volatility index and total return index.
Burning Rock Biotech Limited (BNR) was downgraded to E from E+ on 10/3/2024 due to a noticeable decline in the volatility index and total return index.
E
Sell
7/31/2023Downgrade
Burning Rock Biotech Limited (BNR) was downgraded to E+ from D- on 7/31/2023 due to a decline in the volatility index.
Burning Rock Biotech Limited (BNR) was downgraded to E+ from D- on 7/31/2023 due to a decline in the volatility index.
D
Sell
7/14/2023Upgraded
Burning Rock Biotech Limited (BNR) was upgraded to D- from E+ on 7/14/2023 due to an increase in the growth index and volatility index. Earnings per share increased from -$0.2972 to -$0.2644, EBIT increased 9.99% from -$30.6M to -$27.54M, and total revenue increased 4.06% from $20.02M to $20.83M.
Burning Rock Biotech Limited (BNR) was upgraded to D- from E+ on 7/14/2023 due to an increase in the growth index and volatility index. Earnings per share increased from -$0.2972 to -$0.2644, EBIT increased 9.99% from -$30.6M to -$27.54M, and total revenue increased 4.06% from $20.02M to $20.83M.
E
Sell
5/30/2023Downgrade
Burning Rock Biotech Limited (BNR) was downgraded to E+ from D- on 5/30/2023 due to a decline in the total return index and volatility index.
Burning Rock Biotech Limited (BNR) was downgraded to E+ from D- on 5/30/2023 due to a decline in the total return index and volatility index.
D
Sell
5/15/2023Upgraded
Burning Rock Biotech Limited (BNR) was upgraded to D- from E+ on 5/15/2023 due to an increase in the volatility index.
Burning Rock Biotech Limited (BNR) was upgraded to D- from E+ on 5/15/2023 due to an increase in the volatility index.
E
Sell
4/28/2023Downgrade
Burning Rock Biotech Limited (BNR) was downgraded to E+ from D- on 4/28/2023 due to a decline in the volatility index.
Burning Rock Biotech Limited (BNR) was downgraded to E+ from D- on 4/28/2023 due to a decline in the volatility index.
D
Sell
4/13/2023Upgraded
Burning Rock Biotech Limited (BNR) was upgraded to D- from E+ on 4/13/2023 due to an increase in the total return index and volatility index.
Burning Rock Biotech Limited (BNR) was upgraded to D- from E+ on 4/13/2023 due to an increase in the total return index and volatility index.
E
Sell
3/14/2023Downgrade
Burning Rock Biotech Limited (BNR) was downgraded to E+ from D on 03/14/2023.
Burning Rock Biotech Limited (BNR) was downgraded to E+ from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
Burning Rock Biotech Limited (BNR) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
Burning Rock Biotech Limited (BNR) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
Burning Rock Biotech Limited (BNR) was downgraded to E+ from D- on 02/08/2023.
Burning Rock Biotech Limited (BNR) was downgraded to E+ from D- on 02/08/2023.
D
Sell
1/25/2023Downgrade
Burning Rock Biotech Limited (BNR) was downgraded to D- from D on 1/25/2023 due to a decline in the volatility index and valuation index.
Burning Rock Biotech Limited (BNR) was downgraded to D- from D on 1/25/2023 due to a decline in the volatility index and valuation index.
D
Sell
12/27/2022Upgraded
Burning Rock Biotech Limited (BNR) was upgraded to D from D- on 12/27/2022 due to an increase in the volatility index and total return index.
Burning Rock Biotech Limited (BNR) was upgraded to D from D- on 12/27/2022 due to an increase in the volatility index and total return index.
D
Sell
12/9/2022Downgrade
Burning Rock Biotech Limited (BNR) was downgraded to D- from D on 12/9/2022 due to a decline in the volatility index.
Burning Rock Biotech Limited (BNR) was downgraded to D- from D on 12/9/2022 due to a decline in the volatility index.
D
Sell
11/18/2022Upgraded
Burning Rock Biotech Limited (BNR) was upgraded to D from D- on 11/18/2022 due to an increase in the growth index, volatility index and valuation index. EBIT increased 14.75% from -$40.18M to -$34.25M, earnings per share increased from -$0.3784 to -$0.3252, and total revenue increased 13.98% from $19.8M to $22.57M.
Burning Rock Biotech Limited (BNR) was upgraded to D from D- on 11/18/2022 due to an increase in the growth index, volatility index and valuation index. EBIT increased 14.75% from -$40.18M to -$34.25M, earnings per share increased from -$0.3784 to -$0.3252, and total revenue increased 13.98% from $19.8M to $22.57M.
D
Sell
6/1/2022Downgrade
Burning Rock Biotech Limited (BNR) was downgraded to D- from D on 6/1/2022 due to a decline in the growth index, solvency index and volatility index. Operating cash flow declined 29.39% from -$17.58M to -$22.74M, the quick ratio declined from 4.38 to 3.69, and total revenue declined 7.38% from $23.05M to $21.35M.
Burning Rock Biotech Limited (BNR) was downgraded to D- from D on 6/1/2022 due to a decline in the growth index, solvency index and volatility index. Operating cash flow declined 29.39% from -$17.58M to -$22.74M, the quick ratio declined from 4.38 to 3.69, and total revenue declined 7.38% from $23.05M to $21.35M.
D
Sell
5/16/2022Upgraded
Burning Rock Biotech Limited (BNR) was upgraded to D from E+ on 05/16/2022.
Burning Rock Biotech Limited (BNR) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
Burning Rock Biotech Limited (BNR) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
Burning Rock Biotech Limited (BNR) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
D
Sell
5/4/2022Upgraded
Burning Rock Biotech Limited (BNR) was upgraded to D from E+ on 05/04/2022.
Burning Rock Biotech Limited (BNR) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
Burning Rock Biotech Limited (BNR) was downgraded to E+ from D on 5/1/2022 due to a decline in the solvency index and volatility index. The quick ratio declined from 5.82 to 4.38.
Burning Rock Biotech Limited (BNR) was downgraded to E+ from D on 5/1/2022 due to a decline in the solvency index and volatility index. The quick ratio declined from 5.82 to 4.38.
D
Sell
4/21/2022Upgraded
Burning Rock Biotech Limited (BNR) was upgraded to D from E+ on 4/21/2022 due to an increase in the valuation index.
Burning Rock Biotech Limited (BNR) was upgraded to D from E+ on 4/21/2022 due to an increase in the valuation index.
E
Sell
4/20/2022Downgrade
Burning Rock Biotech Limited (BNR) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index.
Burning Rock Biotech Limited (BNR) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index.
D
Sell
3/2/2022Upgraded
Burning Rock Biotech Limited (BNR) was upgraded to D from D- on 3/2/2022 due to an increase in the volatility index.
Burning Rock Biotech Limited (BNR) was upgraded to D from D- on 3/2/2022 due to an increase in the volatility index.
D
Sell
2/11/2022Downgrade
Burning Rock Biotech Limited (BNR) was downgraded to D- from D on 2/11/2022 due to a decline in the volatility index and total return index.
Burning Rock Biotech Limited (BNR) was downgraded to D- from D on 2/11/2022 due to a decline in the volatility index and total return index.
D
Sell
11/22/2021Upgraded
Burning Rock Biotech Limited (BNR) was upgraded to D from E+ on 11/22/2021 due to a noticeable increase in the growth index. Earnings per share increased from -$0.303 to -$0.2528, and EBIT increased 15.49% from -$31.28M to -$26.44M.
Burning Rock Biotech Limited (BNR) was upgraded to D from E+ on 11/22/2021 due to a noticeable increase in the growth index. Earnings per share increased from -$0.303 to -$0.2528, and EBIT increased 15.49% from -$31.28M to -$26.44M.
E
Sell
11/8/2021Downgrade
Burning Rock Biotech Limited (BNR) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index and volatility index.
Burning Rock Biotech Limited (BNR) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index and volatility index.
D
Sell
9/14/2021Downgrade
Burning Rock Biotech Limited (BNR) was downgraded to D- from D on 9/14/2021 due to a substantial decline in the efficiency index, growth index and volatility index. Operating cash flow declined 27.6% from -$13.68M to -$17.46M, total revenue declined 17.24% from $19.88M to $16.46M, and EBIT declined 13.09% from -$23.45M to -$26.52M.
Burning Rock Biotech Limited (BNR) was downgraded to D- from D on 9/14/2021 due to a substantial decline in the efficiency index, growth index and volatility index. Operating cash flow declined 27.6% from -$13.68M to -$17.46M, total revenue declined 17.24% from $19.88M to $16.46M, and EBIT declined 13.09% from -$23.45M to -$26.52M.
D
Sell
11/20/2020None
Burning Rock Biotech Limited (BNR) was downgraded to D from U on 11/20/2020.
Burning Rock Biotech Limited (BNR) was downgraded to D from U on 11/20/2020.
NASDAQ
03/20/2025 3:18PM Eastern
Quotes delayed
